X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.


最新的帖子

六月 27, 2019

Industry Trends in Biologic Formulations

In 2018, we saw a record-setting year for new-molecular entity (NME) approvals (59) at the FDA1 versus 46 in 2017. 58% were for orphan drugs (patient population less than 200,000 in the US) with 17 biologic-based NME’s. Biosimilars are gaining traction in Europe, in particular. Major factors that are driving the market growth are next-generation business, high growth in chronic diseases, less expensive biosimilar drugs and favorable government regulations.
Victoria Morgan

Victoria Morgan

Director, Segment Marketing, Global Biologics

Categories

Search the Blog

Archive

{1}

{2}
{3}

{4}

  • 以前的博客
    SmartDose Gen II and Gen II

    十一月 06, 2017

    West Announces New Extensions of the SmartDose® Drug Delivery Platform

    Deirdre Swinden

    Deirdre Swinden

    Director, Global Marketing Communications